Stay updated on Fisogatinib in Hepatocellular Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Fisogatinib in Hepatocellular Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fisogatinib in Hepatocellular Carcinoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:53:49.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the Phase 1 study of Fisogatinib (BLU-554) in patients with Hepatocellular Carcinoma, focusing on safety, tolerability, pharmacokinetics, and preliminary antineoplastic activity.
    Difference
    0.1%
    Check dated 2024-06-06T14:50:00.000Z thumbnail image
  7. Check
    26 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying the health conditions and prior treatments required for inclusion. Previously, no information was provided in this section.
    Difference
    17%
    Check dated 2024-05-22T21:32:52.000Z thumbnail image
  8. Check
    47 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:42:37.000Z thumbnail image

Stay in the know with updates to Fisogatinib in Hepatocellular Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fisogatinib in Hepatocellular Carcinoma Clinical Trial page.